Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

Publikation

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

Wissenschaftlicher Artikel/Review - 04.10.2002

Jung Maria-Christina, Zeuzem Stefan, Trojan Jörg, Whitehead Eve, Birtles Emma, Bailey John, Page Mark, Schirren Carl-Albrecht, Diepolder Helmut, Gerlach Tilman, Schraut Winfried, Zachoval Reinhart, Grüner Norbert, Pape Gerd R

Bereiche

Gastroenterologie | Hepatologie

PubMed

12297407

Zitation

Jung M, Zeuzem S, Trojan J, Whitehead E, Birtles E, Bailey J, Page M, Schirren C, Diepolder H, Gerlach T, Schraut W, Zachoval R, Grüner N, Pape G. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002; 20:3598-612.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Vaccine 2002; 20

Veröffentlichungsdatum

04.10.2002

ISSN (Druck)

0264-410X

Seiten

3598-612

Kurzbeschreibung/Zielsetzung

We characterized the anti-viral T-cell response in 22 chronically infected patients, who participated in a European multi-center randomized placebo-controlled, double-blind study therapeutic vaccination trial with pre-S1, pre-S2 and S antigenic components of the hepatitis B virus (HBV). It induced a significant HBsAg-specific T-cell proliferation and the production of Th2-cytokines (i.e. IL-5). A specific induction of Th1-lymphokines was not detectable although this has been demonstrated in this study in response to the nucleocapsid protein (HBcAg). Further analysis indicated that this approach does not activate HBV-specific CD8+ T-lymphocytes as detected by ELISPOT-assay. Our results might explain why a specific therapeutic vaccine, although safe and well-tolerated is not always able to break tolerance leading to the clearance of the hepatitis B virus.